Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation

Radium-223 dichloride (Ra-223) is the first targeted alpha therapy approved for the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastasis. Ra-223 improved overall survival in the international Phase III ALSYMPCA (ALpharadin in SYMPtomatic Prostate Cancer) study....

Descripción completa

Detalles Bibliográficos
Autores principales: Hosono, Makoto, Ikebuchi, Hideharu, Nakamura, Yoshihide, Yanagida, Sachiko, Kinuya, Seigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2018
Materias:
Others
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397713/
https://www.ncbi.nlm.nih.gov/pubmed/30484260
http://dx.doi.org/10.1007/s12149-018-1317-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397713/
https://www.ncbi.nlm.nih.gov/pubmed/30484260
http://dx.doi.org/10.1007/s12149-018-1317-1

Ejemplares similares